BROMOTINE™

Composition:

Each tablet contains: Bromocriptin 2.5 mg as Bromocriptine Mesilate BP

General Description:

Bromotine™ contains Bromocriptine Mesilate, is an ergot derivative with potent dopamine receptor agonist activity. Stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms; Inhibits prolactin which is responsible for lactation and lowers elevated blood levels of growth hormone in acromegaly.
Bromotine™ 28% of oral dose absorbed, 90% to 96% bound to serum albumin and completely metabolized. Major elimination route is via the bile; 2.5% to 5% is excreted in urine and 84.6% is excreted in feces in 120 hrs.

Indication:

• Hyperprolactinemia associated dysfunctions

• Bromocriptine Mesilate tablet is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea.

• Infertility or hypogonadism

• Prolactin secreting adenomas

• Reduction in tumor size in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of

• ocriptine therapy may be used to reduce the tumor mass prior to surgery

• Non-prolactin dependent infertility

• Polycystic Ovary Syndrome (adjuvant therapy to antiestrogenic e.g. clomiphene treatment of anovulation)

• Acromegaly

• Parkinson's disease

Contraindication:

• Sensitivity to ergot alkaloids

• Severe ischemic heart disease or peripheral vascular disease

• Pregnancy

Side Effect:

Abdominal cramps or discomfort, confusion, constipation, depression, diarrhea, dizziness, drop in blood pressure, drowsiness, dry mouth, fainting, fatigue, hallucinations (particularly in Parkinson's patients), headache, inability to sleep, indigestion, light-headedness, loss of coordination, nasal congestion, nausea, shortness of breath, uncontrolled body movement, vertigo, visual disturbance, vomiting, weakness.

Detail prescribing information:

	Detailing Slip	Download